Plain-English translation of NCT06375239 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study designed to evaluate how well different vision tests work in people with inherited retinal diseases like retinitis pigmentosa, choroideremia, and Stargardt disease. Researchers want to understand which tests best measure how the disease affects your daily life and which tests are most accurate and reliable for detecting changes over time.
Currently, researchers don't have a clear understanding of which vision tests are most meaningful for measuring disease progression in inherited retinal diseases. This study aims to identify the best tests so that future clinical trials can more accurately measure whether new treatments are helping patients.
You likely qualify if…
You likely don't qualify if…
You'll visit the specialized low vision research institute for an initial appointment where you'll take a series of vision and function tests. After that, you'll be invited back for a second visit within two weeks, followed by periodic visits over the next year. All testing will take place in a comfortable, familiar setting with experienced low vision specialists, and no medications or procedures are involved.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Sponsor
Ray Therapeutics, Inc.
Collaborators
The Vision Research and Assessment Institute (VRAI)
Enrollment target
~120 participants
Started
April 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shawn Yu, OD
Ray Therapeutics, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.